Strategic Clinical Research Group, LLC

Running trials

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449923· Phase 3· Source

• Not yet recruiting

  A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

  NCT06470373· Phase 3· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

  NCT06668064· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

  NCT06556368· Phase 3· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Source

• Active, not recruiting

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

  NCT06116916· Phase 2· Source

• Active, not recruiting

  Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

  NCT05904691· Phase 1· Source

• Active, not recruiting

  A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

  NCT05224102· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Source

• Completed

  A Single Ascending Dose Cohort Study of AG-73305 in DME Patients

  NCT05301751· Phase 2· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

  NCT05151731· Phase 2· Source

• Completed

  Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

  NCT04708145· Phase 4· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source